<unk>  was generally well tolerated when used in combination with optimized background therapy regimens in treatment-experienced patients with HIV-1 infection in trials of up to 48 weeks' duration.
Raltegravir
Saquinavir
Fosamprenavir
Entecavir
Coronavir
Maribavir
Sorivudine
Telbivudine